The National Drug Code (NDC) is a unique identifier assigned by the U.S. Food and Drug Administration (FDA) to drugs intended for human use, facilitating tracking, reimbursement, and regulatory compliance. This white paper explains the purpose of the NDC, when it must appear on product labels, and why it is not required for Aquabiliti's bulk packaged water-based products, such as Water for Injection (WFI). Aquabiliti's products are designed exclusively for further manufacturing use – serving as components in biopharmaceutical production rather than finished dosage forms for direct parenteral administration. The absence of an NDC does not compromise the product's quality, safety, or suitability for its intended purpose, as these products adhere to stringent U.S. Pharmacopeia (USP) specifications, Current Good Manufacturing Practices (cGMP), and other regulatory standards. By clarifying these distinctions, this document aims to inform customers about appropriate NDC usage and reaffirm Aquabiliti's commitment to delivering high-purity, compliant solutions for the biopharmaceutical industry.
The National Drug Code (NDC) is a universal product identifier for drugs marketed in the United States, established under the Drug Listing Act of 1972 and administered by the FDA. It consists of a 10- or 11-digit numeric code divided into three segments: the labeler code (4-6 digits, assigned by the FDA to the manufacturer, repackager, or distributor), the product code (3-4 digits, identifying the drug's strength, dosage form, and formulation), and the package code (1-2 digits, specifying package size and type). For example, an NDC might appear as 12345-6789-01.
The NDC serves multiple purposes, such as enabling accurate drug identification for prescribing, dispensing, and administration, facilitating pharmacovigilance, recalls, and supply chain tracking, and ensuring compliance with FDA regulations for drug listing and labeling.
NDCs are published in the FDA's NDC Directory, which includes information on finished drugs (prescription, over-the-counter, and insulin products), unfinished drugs (e.g., active pharmaceutical ingredients or APIs), and compounded drugs submitted via Structured Product Labeling (SPL) electronic filings.
Under FDA regulations (21 CFR Part 207), an NDC is required for all drugs subject to listing, which includes finished drug products and certain unfinished drugs intended for commercial distribution in the U.S. Specifically:
Finished Drug Products: These are ready-to-use dosage forms, such as tablets, capsules, injectables, or solutions packaged for direct administration to patients. Prescription drugs, over-the-counter (OTC) medications, and biologics in final form must bear an NDC on their labels and outer packaging. This includes sterile water for injection labeled for immediate medical use, such as dilution or irrigation during procedures.
Unfinished Drugs: Bulk APIs or intermediates that are further processed into finished drugs may require an NDC if they are listed with the FDA. However, this applies primarily to active ingredients, not excipients or processing aids.
Labeling Requirements: The NDC must appear on the product label in a human-readable format and often as a barcode to support automated systems. It is mandatory for products regulated under the Federal Food, Drug, and Cosmetic (FD&C) Act as drugs, ensuring traceability from manufacturer to end-user.
NDCs are not required for:
Medical devices, dietary supplements, or cosmetics (unless classified as drugs).
Bulk excipients, solvents, or components intended solely for further manufacturing or compounding, where the product is not in its final dosage form nor labeled for direct patient use (i.e., Aquabiliti’s bulk packaged water-based products).
Products exported without U.S. marketing or those not subject to FDA drug listing.
Aquabiliti specializes in high-purity, sterile aqueous solutions, including bulk packaged Water for Injection (WFI) in sizes ranging from 125mL to 1,100L, housed in proprietary single-use bioprocess containers, bottles, and hybrid bottle bags. These products are explicitly designed and labeled for further manufacturing use and not for direct parenteral administration to patients.
Classification as Components, Not Finished Drugs: Per USP and FDA guidelines, WFI is an essential excipient or ingredient material used in the production of parenteral drug products. Bulk WFI, like that offered by Aquabiliti, is an intermediate supplied to manufacturers for incorporation into final formulations. It is not a finished dosage form ready for patient use, which distinguishes it from products that carry NDCs and are labeled for direct injection or infusion.
Intended Use Exemption: FDA regulations (21 CFR § 207.33) mandate NDCs for drugs subject to listing, but bulk excipients for further processing are exempt because they are not marketed as standalone drugs. Aquabiliti's labeling clearly states the products' intended use for manufacturing, aligning with cGMP requirements for pharmaceutical waters (e.g., USP <1231> Water for Pharmaceutical Purposes). Requiring an NDC would imply classification as a finished drug, which is inappropriate and could mislead users about its application.
Regulatory Precedent: Bulk pharmaceutical waters and excipients are routinely supplied without NDCs, as they fall under supplier qualification and material control rather than drug product listing. For instance, APIs require NDCs if listed as unfinished drugs, but passive components like WFI do not, provided they meet pharmacopeial standards.
The lack of an NDC on Aquabiliti's bulk packaged WFI and similar products does not diminish their quality, efficacy, or compliance for intended applications. On the contrary, these products are engineered to exceed regulatory expectations through rigorous controls.
Aquabiliti's WFI meets or surpasses USP <645> for conductivity, <643> for Total Organic Carbon (TOC), <85> for bacterial endotoxins, <788> for Particulate Matter, and <71> for Sterility, regardless of NDC status. Real-time stability studies confirm long-term integrity, with all test levels remaining well within USP specifications across all container sizes. Production follows 21 CFR Parts 210, 211, and 820, including validated processes for WFI generation, formulation and bulk filling, and sterility assurance. Certificates of Analysis (CoAs) provide full traceability, lot-specific testing data, and confirmation of pharmacopeial compliance – equivalent to documentation for NDC-bearing products.
As components for further manufacturing, Aquabiliti's products enable downstream processes like API dilution or buffer preparation without compromising final drug quality. Customers can qualify Aquabiliti as a supplier through audits, risk assessments, and material testing, ensuring seamless integration into their cGMP operations. Additionally, not having an NDC does not affect pharmacovigilance, as these are not patient-facing drugs. Instead, quality is upheld through ISO 13485-certified systems, leachables/extractables studies, and process validations, providing assurance comparable to or exceeding that of NDC-labeled equivalents.
The NDC is a vital tool for identifying and regulating finished drugs, but it is not universally required across all pharmaceutical materials. For Aquabiliti's bulk packaged WFI and water-based products – intended exclusively for further manufacturing – the absence of an NDC is appropriate and aligns with FDA and USP guidelines. This approach ensures compliance without implying misuse as a finished drug, while the products continue to meet the highest standards of purity and quality. Customers can rely on Aquabiliti for reliable, high-performance solutions that support their processes without unnecessary regulatory overhead. For more information on Aquabiliti’s water-based products, please visit www.aquabiliti.com or contact our team at customercare@aquabiliti.com.